SKYE — Skye Bioscience, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1516551 ·
Last close
$1.68
Market Cap
$7.44M
52W High
$14.08
52W Low
$1.50
ADV30
72,859
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -7,811,303 | -10,786,594 | 11,033,795 | 8,068,357 | 11,531,102 |
| Mar 2026 | 0 | — | -12,674,366 | -12,509,361 | 19,416,736 | 8,149,015 | 10,404,932 |
| Dec 2025 | 0 | — | -14,895,544 | -14,441,963 | 28,313,633 | 5,882,498 | 8,289,458 |
| Sep 2025 | 0 | — | -13,264,534 | -12,754,660 | 41,324,289 | 18,441,079 | 8,488,104 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-42,434,966
Investing CF
$4,204,636
Financing CF
$-41,954
CapEx
$-56,336
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.44
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-199,383,847
Inventory
—
Receivables
$9,525
ST Investments
$8,959,614
EBIT TTM
$-57,325,257
Pretax Income TTM
$-57,327,456
Interest Exp TTM
$2,199
Analysts
4
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -58,163,565 | -55,924,814 | 28,313,633 | 8,289,458 | 20,024,175 | -43,062,529 |
| Dec 2024 | 0 | -36,427,435 | -26,567,123 | 72,763,773 | 4,612,049 | 68,151,724 | -25,237,480 |
| Dec 2023 | 0 | -13,671,801 | -37,644,784 | 11,940,411 | 14,072,229 | -2,131,818 | -13,952,178 |
| Dec 2022 | 0 | -12,106,422 | -19,481,602 | 9,111,072 | 12,119,126 | -3,008,054 | -12,744,072 |
TTM Snapshot
Revenues TTM
$2,333,342
NetIncome TTM
$-57,330,856
OpCashFlow TTM
—
Assets (Latest)
$19,416,736
Forward EPS
$-7.40
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| CURX | Curanex Pharmaceuticals Inc | $7.46M | $4.76 | — |
| FBLG | FibroBiologics, Inc. | $7.39M | $1.11 | — |
| TRAW | Traws Pharma, Inc. | $7.38M | $0.48 | — |
| SNGX | SOLIGENIX, INC. | $7.54M | $0.35 | — |
| INM | InMed Pharmaceuticals Inc. | $7.31M | $1.33 | — |
News headlines (Yahoo Finance, 1h cache)
Skye Bioscience Inc (SKYE) (Q2 2026) Earnings Call Highlights: Strategic Pivot to Fibrex ...
2026-08-17 17:32 · Yahoo
Skye Bioscience and Redx Pharma Announce Transaction Agreement and $125 Million in Financings
2026-08-14 13:33 · Yahoo
The weight-loss drugs boom is creating both winners and wipeouts: One Big Investment Idea
2026-07-17 10:39 · Yahoo
Skye Announces Cohort Review Committee Approved Opening of Cohort 2 Based on Favorable Safety Data from First Four Participants Treated in Cohort 1
2026-05-20 11:00 · Yahoo
UPDATE – Skye Bioscience Reports First Quarter 2026 Financial Results and Business Update
2026-05-12 17:33 · Yahoo
Skye Bioscience Reports First Quarter 2026 Financial Results and Business Update
2026-05-11 20:01 · Yahoo
Skye Bioscience Presenting at GLP-1-Based Therapeutics Summit
2026-04-07 11:00 · Yahoo
Skye Bioscience Treats First Patient in Nimacimab Higher-Dose Expansion Study Evaluating Exposure-Response to Inform Phase 2b Dose Selection for GLP-1 Combination Development
2026-04-02 11:00 · Yahoo
Halozyme Therapeutics Touts $1.8B Revenue Outlook, ENHANZE Royalties and New Hypercon Deals at Conference
2026-03-18 05:06 · Yahoo
Skye Bioscience Inc (SKYE) Q4 2025 Earnings Call Highlights: Pioneering Advances in Obesity ...
2026-03-12 01:04 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.